T-cell epitope peptide vaccines.
T-cell immunotherapy is a promising treatment option for cancer. The identification of tumor antigens that are recognized by the immune system has allowed for the generation of vaccines for various malignancies. Due to the ease of manufacturing and characterizating peptide-based vaccines they have been used to stimulate antitumor T-cells. This article will review the use of peptide-based vaccines for the treatment of cancer by inducing antitumor T-lymphocyte responses.
Elsawa
Sherine F
SF
Department of Immunology, Mayo Clinic, Rochester, MN, USA. elsawa.sherine@mayo.edu
Rodeberg
David A
DA
Celis
Esteban
E
D000276:Adjuvants, Immunologic; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology; D022223:Vaccines, Subunit / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D022223:Vaccines, Subunit